{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T04:58:54Z","timestamp":1792904334040,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jtct.2022.02.016","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T19:05:15Z","timestamp":1645556715000},"page":"260.e1-260.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cytokine Release Syndrome during Antithymocyte Globulin\/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9715-5054","authenticated-orcid":false,"given":"Hanna A.","family":"Knaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Rottner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara K.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Cserna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Mitterbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schulenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Rabitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5628-7942","authenticated-orcid":false,"given":"Philipp","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.02.016_bib0001","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41409-018-0393-0","article-title":"Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis","volume":"54","author":"Kumar","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0002","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0003","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.02.016_bib0005","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S2352-3026(17)30081-9","article-title":"Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial","volume":"4","author":"Finke","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0006","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1200\/JCO.20.00150","article-title":"Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study","volume":"38","author":"Chang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0007","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0008","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.02.016_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.bmt.1703640","article-title":"The impact of antithymocyte globulin on short-term toxicity after allogeneic stem cell transplantation","volume":"30","author":"Pihusch","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/sj.bmt.1701991","article-title":"Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation","volume":"24","author":"Remberger","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0012","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.016_bib0013","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.016_bib0014","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2022.02.016_bib0015","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/bmt.2009.359","article-title":"Regression modeling of competing risk using R: an in depth guide for clinicians","volume":"45","author":"Scrucca","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0016","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41409-020-0792-x","article-title":"Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel","volume":"55","author":"Bonifazi","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0017","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/ajt.15642","article-title":"Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies","volume":"20","author":"Turki","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2022.02.016_bib0018","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","article-title":"Population pharmacokinetic modeling of Thymoglobulin\u00ae in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing","volume":"54","author":"Admiraal","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtct.2022.02.016_bib0019","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s00277-016-2758-z","article-title":"Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation","volume":"95","author":"Ecsedi","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0020","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(17)30417-5","article-title":"Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Locatelli","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0021","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1007\/s00277-021-04521-z","article-title":"Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience","volume":"100","author":"Butera","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0022","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1705295","article-title":"Differential effect of conditioning regimens on cytokine responses during allogeneic stem cell transplantation","volume":"37","author":"Andersen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2022.02.016_bib0023","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1182\/blood-2019-132088","article-title":"Tocilizumab for prophylaxis of cytokine release syndrome after outpatient-based haploidentical T-cell replete peripheral blood stem cell transplantation","volume":"134","author":"Marquez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.016_bib0024","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1182\/blood.2020009050","article-title":"A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin\/methotrexate GVHD prophylaxis","volume":"137","author":"Kennedy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.016_bib0025","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.02.016_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellimm.2014.02.007","article-title":"Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation","volume":"288","author":"Kato","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.jtct.2022.02.016_bib0027","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1086\/314602","article-title":"Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients","volume":"179","author":"Humar","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2022.02.016_bib0028","first-page":"S200","article-title":"ATOS: a prospective multicenter non interventional observational study on the use of ATLG-Grafalon in unrelated donor transplantation in adults with hematological malignancies","volume":"52","author":"Finke","year":"2017","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:04:00Z","timestamp":1763003040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2666636722000963"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine Release Syndrome during Antithymocyte Globulin\/Anti-T Lymphocyte Globulin Serotherapy for Graft-versus-Host Disease Prophylaxis before Allogeneic Hematopoietic Stem Cell Transplantation: Incidence and Early Clinical Impact According to American Society of Transplantation and Cellular Therapy Grading Criteria","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}